Steichert, M.; Cawello, W.; Burckhardt, B.B.; Suessenbach, F.K.; Laeer, S.; on behalf of the LENA Consortium.
Angiotensin II/Angiotensin I Ratio as a New Pharmacodynamic Parameter for Population Modelling in Healthy Adults and Children with Heart Failure Treated with Enalapril. Pharmaceutics 2025, 17, 1345.
https://doi.org/10.3390/pharmaceutics17101345
AMA Style
Steichert M, Cawello W, Burckhardt BB, Suessenbach FK, Laeer S, on behalf of the LENA Consortium.
Angiotensin II/Angiotensin I Ratio as a New Pharmacodynamic Parameter for Population Modelling in Healthy Adults and Children with Heart Failure Treated with Enalapril. Pharmaceutics. 2025; 17(10):1345.
https://doi.org/10.3390/pharmaceutics17101345
Chicago/Turabian Style
Steichert, Melina, Willi Cawello, Bjoern B. Burckhardt, Fabian K. Suessenbach, Stephanie Laeer, and on behalf of the LENA Consortium.
2025. "Angiotensin II/Angiotensin I Ratio as a New Pharmacodynamic Parameter for Population Modelling in Healthy Adults and Children with Heart Failure Treated with Enalapril" Pharmaceutics 17, no. 10: 1345.
https://doi.org/10.3390/pharmaceutics17101345
APA Style
Steichert, M., Cawello, W., Burckhardt, B. B., Suessenbach, F. K., Laeer, S., & on behalf of the LENA Consortium.
(2025). Angiotensin II/Angiotensin I Ratio as a New Pharmacodynamic Parameter for Population Modelling in Healthy Adults and Children with Heart Failure Treated with Enalapril. Pharmaceutics, 17(10), 1345.
https://doi.org/10.3390/pharmaceutics17101345